Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px

Document › Details

Evotec AG. (1/30/17). "Press Release: Evotec to Attend Three Upcoming Investor Conferences". Hamburg.

	Organisation	Evotec AG (FSE: EVT, TecDAX)
	Today	Evotec SE (FSE: EVT, MDA X/TecDAX, Nasdaq: EVO)
	Group	Evotec (Group)
	Organisation 2	Bankhaus Lampe KG
	Group	Oetker (Group)
	Product	conference, investment / investor / financing / VC
	Product 2	drug discovery services
	Person	Lanthaler, Werner (Evotec AG 200903– CEO before Intercell AG CFO before Austrian Industrial Assoc before McKinsey)
	Person 2	Hansen, Gabriele (Evotec 201404 VP Corporate Communications + Investor Relations)

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at the Jefferies' 2017 Celgene Collaborators Summit in New York City, USA, and will be attending the Bankhaus Lampe German Equity Forum, London, UK, and the 11th ODDO German Conference, Frankfurt, Germany.

Bankhaus Lampe German Equity Forum, London, UK
Date: Thursday, 02 February 2017
Venue: London, UK
Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG

11th ODDO German Conference, Frankfurt, Germany
Date: Thursday, 16 February 2017
Venue: Frankfurt, Germany
Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG

Jefferies' 2017 Celgene Collaborators Summit, New York City, USA
Date: Tuesday, 21 February 2017
Venue: New York City, USA
Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. Janssen Pharmaceuticals in the field of Alzheimer's disease, with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and with Celgene in the field of neurodegenerative diseases. For additional information please go to www.evotec.com.

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec AG:

Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com

Record changed: 2023-06-05